Successful hepatitis B immunization in non- and low responding health care workers

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 725-728

  Heininger, Ulrich ^a   Gambon, Muriel ^a   Gruber, Verena ^b   Margelli, Daniela ^c  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b Kantonsspital Bruderholz   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Health care workers; Hepatitis B; Immunization; Low responder; Non responder; Serology; Vaccine

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ARTICLE; BODY MASS; HEALTH CARE PERSONNEL; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; TREATMENT OUTCOME;

EID: 78649345327     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12420     Document Type: Article

References (17)

1. Puro V, De Carli G, Cicalini S, Soldani F, Balslev U, Begovac J, et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill 2005; 10:260-4.
2. Bundesamt für Gesundheit. Impfempfehlungen für Beschäftigte im Gesundheitswesen. BAG Bulletin 2009; 43:804-8.
3. Clemens R, Sanger R, Kruppenbacher J, Hobel W, Stanbury W, Bock HL, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a post-marketing surveillance. Vaccine 1997; 15:349-52.
4. Huzly D, Schenk T, Jilg W, Neumann-Haefelin D. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008; 46:1298-306.
5. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989; 87:14-20.
6. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998; 15:1-8.
7. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986; 13:39-45.
8. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al. Genetic prediction of non-response to hepatitis B vaccine. N Engl J Med 1989; 321:708-12.
9. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002; 35:1368-75.
10. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
11. Shaw FE Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-30.
12. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. Jama 1993; 270:2935-9.
13. Poland GA. Hepatitis B immunization in health care workers. Dealing with vaccine nonresponse. Am J Prev Med 1998; 15:73-7.
14. Sangare L, Manhart L, Zehrung D, Wang CC. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009; 27:1777-86.
15. Ambrosch F, Wiedermann G, Andre FE, Delem A, Gregor H, Hofmann H, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994; 44:452-6.
16. Bertino JS Jr, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997; 175:678-81.
17. Pichichero ME. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin 2008; 4:262-70.